Avian Influenza Vaccination in Chickens and Pigs with Replication-Competent Adenovirus–Free Human Recombinant Adenovirus 5

Toro, Haroldo; Ginkel, Frederik W. van; Tang, De-chu C.; Schemera, Bettina; Rodning, Soren P.; Newton, Joseph C.

doi:10.1637/8773-033109-reg.1

Cited by 18 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPAI of the H5 and H7 subtypes remain a constant concern in the world poultry industry. This has led the World Organization for Animal Health and the Food and Agricultural Organization of the United Nations to recommend vaccination of poultry . Several viral vectors expressing HA constructs have been shown to be immunogenic and protective against HPAI challenge .…”

Section: Resultsmentioning

confidence: 99%

Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA‐NP+M1 coadministration with inactivated influenza vaccine

et al. 2013

View full text Add to dashboard Cite

Licensed seasonal influenza vaccines induce antibody (Ab) responses against influenza hemagglutinin (HA) that are limited in their ability to protect against different strains of influenza. Cytotoxic T lymphocytes recognizing the conserved internal nucleoprotein (NP) and matrix protein (M1) are capable of mediating a cross-subtype immune response against influenza. Modified vaccinia Ankara (MVA) virus encoding NP and M1(MVA-NP+M1) is designed to boost preexisting T-cell responses in adults in order to elicit a cross-protective immune response. We examined the coadministration of HA protein formulations and candidate MVA-NP+M1 influenza vaccines in murine, avian, and swine models. Ab responses postimmunization were measured by ELISA and pseudotype neutralization assays. Here, we demonstrate that MVA-NP+M1 can act as an adjuvant enhancing Ab responses to HA while simultaneously inducing potent T-cell responses to conserved internal Ags. We show that this regimen leads to the induction of cytophilic Ab isotypes that are capable of inhibiting hemagglutination and in the context of H5 exhibit cross-clade neutralization. The simultaneous induction of T cells and Ab responses has the potential to improve seasonal vaccine performance and could be employed in pandemic situations. Keywords: Adjuvants r Influenza vaccines r T cells r VaccinationAdditional supporting information may be found in the online version of this article at the publisher's web-site IntroductionFor the past 60 years, vaccination has and continues to be the main method to combat both seasonal and pandemic influenza. While Correspondence: Caitlin E. Mullarkey e-mail: caitlin.mullarkey@ndm.ox.ac.uk the strains included in seasonal influenza vaccines are updated regularly, in over half a century there have been few changes in the overall vaccination strategy. It is well established that licensed influenza vaccines work by eliciting neutralizing antibodies against the surface hemagglutinin (HA) protein, yet these antibodies confer little or no protection against distinct subtypes [1]. Subsequently, the efficacy of existing vaccines is highly dependent on correctly matching vaccine strains with circulating influenza C 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu Eur. J. Immunol. 2013. 43: 1940-1952 Clinical immunology 1941 strains [2]. Protection rates vary year to year and are estimated in healthy adults to be between 60 and 90% when the strains are correctly matched [3]. However, a recent meta-analysis assessing the efficacy and effectiveness of seasonal influenza vaccines suggests that protection rates may be overestimated [4]. Moreover, protection rates in the elderly are even lower despite the fact that this demographic accounts for 90% of influenza-related mortality and is a key target in vaccination campaigns [4]. There is a vital need to develop more effective influenza vaccines and to reevaluate influenza vaccination strategies especially with regard to pandemic preparedness. "Universal flu vaccines" that elicit cross-protect...

show abstract

Section: Resultsmentioning

confidence: 99%

Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA‐NP+M1 coadministration with inactivated influenza vaccine

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Another study of live IB vaccination in 1-day-old chickens also showed an inefficient antibody response and the protective efficacy of the vaccine mostly correlated with induction of high levels of CD4+, CD8+ and IgA bearing B cells [ 64 ]. Also, the vaccination of 1 day old chickens with adenovirus vectored H5 and H7 influenza vaccine could induce IgA response in lachrymal fluid and increased interleukin-6 expression without inducing detectable levels of serum antibodies [ 65 ]. Therefore, our current findings are consistent with previous reports in that LAIV enhances mucosal IgA response and provides viral clearance that is less dependent on serum antibody response in young chickens.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and synergy of live-attenuated and inactivated influenza vaccines in young chickens

Jang

Elaish

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

Outbreaks of novel highly pathogenic avian influenza viruses have been reported in poultry species in the United States since 2014. These outbreaks have proven the limitations of biosecurity control programs, and new tools are needed to reinforce the current avian influenza control arsenal. Some enzootic countries have implemented inactivated influenza vaccine (IIV) in their control programs, but there are serious concerns that a long-term use of IIV without eradication may result in the selection of novel antigenically divergent strains. A broadly protective vaccine is needed, such as live-attenuated influenza vaccine (LAIV). We showed in our previous studies that pc4-LAIV (a variant that encodes a C-terminally truncated NS1 protein) can provide significant protection against heterologous challenge virus in chickens vaccinated at 2–4 weeks of age through upregulation of innate and adaptive immune responses. The current study was conducted to compare the performances of pc4-LAIV and IIV in young chickens vaccinated at 1 day of age. A single dose of pc4-LAIV was able to induce stronger innate and mucosal IgA responses and protect young immunologically immature chickens better than a single dose of IIV. Most importantly, when 1-day-old chickens were intranasally primed with pc4-LAIV and subcutaneously boosted with IIV three weeks later, they showed a rapid, robust, and highly cross-reactive serum antibody response and a high level of mucosal IgA antibody response. This vaccination regimen warrants further optimization to increase its range of protection.

show abstract

“…Administration of the bivalent vaccine by a mass vaccination route by course spray to 1-day-old chickens induced local IgA antibodies in tears but no detectable serum antibodies [231]. Importantly, the induction of anti-H7 antibodies was not impaired even in the presence of anti-Ad5 antibodies [229,231].…”

Section: Adenovirus (Ad-5)mentioning

confidence: 93%

“…In ovo vaccination with monovalent adenovirus-H7 or bivalent adenovirus H7-H5 HA recombinant vaccines induced high antibody titres between 25 and 45 days after hatch [229,231]. Administration of the bivalent vaccine by a mass vaccination route by course spray to 1-day-old chickens induced local IgA antibodies in tears but no detectable serum antibodies [231]. Importantly, the induction of anti-H7 antibodies was not impaired even in the presence of anti-Ad5 antibodies [229,231].…”

Section: Adenovirus (Ad-5)mentioning

confidence: 97%

“…An intramuscular injection of chickens with this vaccine at age 4 weeks elicited high antibody titres and all chickens were protected after challenge with a heterologous H7N3 HPAIV at 8 weeks p.v. In ovo vaccination with monovalent adenovirus-H7 or bivalent adenovirus H7-H5 HA recombinant vaccines induced high antibody titres between 25 and 45 days after hatch [229,231]. Administration of the bivalent vaccine by a mass vaccination route by course spray to 1-day-old chickens induced local IgA antibodies in tears but no detectable serum antibodies [231].…”

Section: Adenovirus (Ad-5)mentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and control of H7 avian influenza viruses in birds and humans

2014

View full text Add to dashboard Cite

The H7 subtype HA gene has been found in combination with all nine NA subtype genes. Most exhibit low pathogenicity and only rarely high pathogenicity in poultry (and humans). During the past few years infections of poultry and humans with H7 subtypes have increased markedly. This review summarizes the emergence of avian influenza virus H7 subtypes in birds and humans, and the possibilities of its control in poultry. All H7Nx combinations were reported from wild birds, the natural reservoir of the virus. Geographically, the most prevalent subtype is H7N7, which is endemic in wild birds in Europe and was frequently reported in domestic poultry, whereas subtype H7N3 is mostly isolated from the Americas. In humans, mild to fatal infections were caused by subtypes H7N2, H7N3, H7N7 and H7N9. While infections of humans have been associated mostly with exposure to domestic poultry, infections of poultry have been linked to wild birds or live-bird markets. Generally, depopulation of infected poultry was the main control tool; however, inactivated vaccines were also used. In contrast to recent cases caused by subtype H7N9, human infections were usually self-limiting and rarely required antiviral medication. Close genetic and antigenic relatedness of H7 viruses of different origins may be helpful in development of universal vaccines and diagnostics for both animals and humans. Due to the wide spread of H7 viruses and their zoonotic importance more research is required to better understand the epidemiology, pathobiology and virulence determinants of these viruses and to develop improved control tools.

show abstract

Avian Influenza Vaccination in Chickens and Pigs with Replication-Competent Adenovirus–Free Human Recombinant Adenovirus 5

Cited by 18 publications

References 30 publications

Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA‐NP+M1 coadministration with inactivated influenza vaccine

Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA‐NP+M1 coadministration with inactivated influenza vaccine

Efficacy and synergy of live-attenuated and inactivated influenza vaccines in young chickens

Prevalence and control of H7 avian influenza viruses in birds and humans

Contact Info

Product

Resources

About